Accelerating Antimicrobial Innovation: Ecraid and INCATE Announce Strategic Partnership

Bridging Discovery and Clinical Validation

Both organisations share closely aligned missions and are well positioned to address the development of new antimicrobial solutions.

By combining INCATE’s support of early-stage ventures with Ecraid’s robust clinical research infrastructure, the partnership creates a strong continuum from early discovery to clinical validation. This integrated approach will support the development of urgently needed treatments and interventions to address antimicrobial resistance.

Strengthening the Innovation Pipeline

Through this partnership, ventures within INCATE’s portfolio will benefit from Ecraid’s expertise and network as they progress along the development pathway. 

For Ecraid, this collaboration further strengthens its role across the antimicrobial innovation pipeline by extending its engagement to earlier-stage translational projects. By supporting and guiding these initiatives, Ecraid aims to help accelerate the successful development of new treatment modalities to combat antimicrobial resistance.

Joint Educational Initiatives 

Beyond technical consultation, Ecraid and INCATE will establish joint educational events to support the innovators within the AMR community. These initiatives will focus on providing tools to entrepreneurs to learn how to navigate the complexities of clinical evaluation, ensuring that the next generation of antimicrobials is not only scientifically sound but also clinically actionable.

Collaboration for Global Impact

The fight against antimicrobial resistance requires strong partnerships across academia, clinical research, policy makers and innovation ecosystems.

By joining forces, Ecraid and INCATE are taking another important step toward accelerating the development of new antimicrobial interventions and strengthening the global response to AMR.